MONTEREY PARK, CA – February 2, 2011 – GeneFluidics, Inc. is pleased to announce a joint publication with Stanford University, University of Arizona, and Veterans Affairs Palo Alto which has made the cover of The Journal of Urology, the Official Journal of the American Urological Association.
In this joint publication, GeneFluidics’ research partners demonstrate the clinical validation of the GeneFluidics electrochemical detection platform for the purpose of rapid antimicrobial susceptibility testing directly from clinical urine samples. In this study, the results were obtained within 3.5 hours.
A significant barrier to effective management of antibiotic-resistant organisms is the current standard diagnostic methodologies which provide results after days rather than hours. Without point-of-care diagnostics, physicians must act without completely information in order to treat patients with rapidly progressive diseases. A point-of-care device would revolutionize antibiotic management of infections. This new study demonstrates the viability of GeneFluidics’ electrochemical platform in eventually replacing the existing methodologies with future point-of-care technology, currently under development at GeneFluidics.
The complete publication is available for free on The Journal Of Urology’s website.
GeneFluidics was incorporated in 2000 to develop a fast, accurate, and simple testing system for improving worldwide health. By integrating novel bionano electrochemical technologies, the company’s revolutionary sensor platform enables bioassays to be performed in under an hour with sensitivity to picogram/ml concentrations for immunoassays and femtomolar concentrations for genetic assays, without the use of PCR.
For more information on GeneFluidics, contact:
845 Meridian Street, Irwindale, CA 91010
Phone: 626 263-3060
NOTE: Contact information on this page for GeneFluidics was updated from the original press release, which used the previous address and phone number for the company.